Uralyt Urato

Uralyt Urato may be available in the countries listed below.

Ingredient matches for Uralyt Urato

Potassium Citrate

Potassium Citrate is reported as an ingredient of Uralyt Urato in the following countries:

• Spain

International Drug Name Search

Zuracyn

Zuracyn may be available in the countries listed below.

Ingredient matches for Zuracyn

Erythromycin

Erythromycin is reported as an ingredient of Zuracyn in the following countries:

• Bangladesh

International Drug Name Search

Armolev

Armolev may be available in the countries listed below.

Ingredient matches for Armolev

Levofloxacin

Levofloxacin is reported as an ingredient of Armolev in the following countries:

• Indonesia

International Drug Name Search

Juvisync

Juvisync is a brand name of simvastatin/sitagliptin, approved by the FDA in the following formulation(s):

JUVISYNC (simvastatin; sitagliptin phosphate - tablet; oral)

• 
  Manufacturer: MERCK SHARP DOHME
  
  Approval date: October 7, 2011
  
  Strength(s): 10MG;EQ 100MG BASE, 20MG;EQ 100MG BASE, 40MG;EQ 100MG BASE ^[RLD]

Has a generic version of Juvisync been approved?

No. There is currently no therapeutically equivalent version of Juvisync available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Juvisync. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
  Patent 6,303,661
  Issued: October 16, 2001
  Inventor(s): Demuth; Hans-Ulrich & Rosche; Fred & Schmidt; Joem & Pauly; Robert P. & McIntosh; Christopher H. S. & Pederson; Ray A.
  Assignee(s): Probiodrug
  Novel therapeutic regimens are provided which comprise the administration of therapeutically effective amounts of an inhibitor to dipeptidyl peptidase (DP-IV) or enzymes of similar activity whereby their ability to degrade the incretins, GLP-1 and GIP, is reduced. As a result hyperglycemia, such as that accompanying food intake may be reduced due to improved insulin release. A preferred therapeutic regimen amongst a number of routes of administration and inhibitors that may be used comprises the oral administration of isoleucyl thiazolidine.
  
  Patent expiration dates:
  
  
  • April 24, 2017
    
    ✓ 
    Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE
  
  



• 
  Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
  Patent 6,699,871
  Issued: March 2, 2004
  Inventor(s): Scott D.; Edmondson & Michael H.; Fisher & Dooseop; Kim & Malcolm; Maccoss & Emma R.; Parmee & Ann E.; Weber & Jinyou; Xu
  Assignee(s): Merck & Co., Inc.
  The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
  
  Patent expiration dates:
  
  
  • July 26, 2022
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Method of regulating glucose metabolism, and reagents related thereto
  Patent 6,890,898
  Issued: May 10, 2005
  Inventor(s): Bachovchin; William W. & Plaut; Andrew G. & Drucker; Daniel
  Assignee(s): Trustees of Tufts College
  1149336 Ontario Inc.
  New England Medical Center Hospitals, Inc.
  The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis.
  
  Patent expiration dates:
  
  
  • February 2, 2019
    
    ✓ 
    Patent use: METHOD OF TX TYPE 2 DM IN PTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBO WITH AN AGENT ACTING ON AN ATP-DEPENDENT CHANNEL IN BETA CELLS SUCH AS A SULFYONYLUREA(INCL GLIPIZIDE, GLIMEPIRIIDE & GLYBURIDE)
  
  
  
  • February 2, 2019
    
    ✓ 
    Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH INSULIN
  
  
  
  • February 2, 2019
    
    ✓ 
    Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH METFORMIN
  
  



• 
  Method of regulating glucose metabolism, and reagents related thereto
  Patent 7,078,381
  Issued: July 18, 2006
  Inventor(s): Bachovchin; William W. & Plaut; Andrew G. & Drucker; Daniel
  Assignee(s): Trustees of Tufts College
  The present invention provides methods and compositions for modifying glucose metabolism and treating Type II diabetes in an animal, along with modifying metabolism of a peptide hormone in an animal. Compositions disclosed herein comprise one or more peptides and/or peptide analogs which include a functional group that reacts with an active site residue of a protease.
  
  Patent expiration dates:
  
  
  • February 2, 2019
    
    ✓ 
    Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE
  
  



• 
  Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
  Patent 7,125,873
  Issued: October 24, 2006
  Inventor(s): Edmondson; Scott D & Fisher; Michael H. & Kim; Dooseop & Maccoss; Malcolm & Parmee; Emma R. & Weber; Ann E & Xu; Jinyou
  Assignee(s): Merck & Co., Inc.
  The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
  
  Patent expiration dates:
  
  
  • July 26, 2022
    
    ✓ 
    Patent use: METHOD OF TREATING TYPE 2 DIABETES MELITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A PPAR-GAMMA AGONIST (SUCH AS PIOGLITAZONE AND ROSIGLITAZONE)
    ✓ 
    Drug product
  
  
  
  • July 26, 2022
    
    ✓ 
    Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A SULFONYLUREA (SUCH AS GLIPIZIDE, GLIMEPIRIDE AND GLYBURIDE)
    ✓ 
    Drug product
  
  
  
  • July 26, 2022
    
    ✓ 
    Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH INSULIN
    ✓ 
    Drug product
  
  
  
  • July 26, 2022
    
    ✓ 
    Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH METFORMIN
    ✓ 
    Drug product
  
  



• 
  Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
  Patent 7,326,708
  Issued: February 5, 2008
  Inventor(s): Cypes; Stephen Howard & Chen; Alex Minhua & Ferlita; Russell R. & Hansen; Karl & Lee; Ivan & Vydra; Vicky K. & Wenslow, Jr.; Robert M.
  Assignee(s): Merck & Co., Inc.
  The dihydrogenphosphate salt of 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine is a potent inhibitor of dipeptidyl peptidase-IV and is useful for the prevention and/or treatment of non-insulin dependent diabetes mellitus, also referred to as type 2 diabetes. The invention also relates to a crystalline monohydrate of the dihydrogenphosphate salt as well as a process for its preparation, pharmaceutical compositions containing this novel form and methods of use for the treatment of diabetes, obesity, and high blood pressure.
  
  Patent expiration dates:
  
  
  • April 11, 2026
    
    ✓ 
    Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Method of regulating glucose metabolism, and reagents related thereto
  Patent 7,459,428
  Issued: December 2, 2008
  Inventor(s): Bachovchin; William W. & Plaut; Andrew G. & Drucker; Daniel
  Assignee(s): Trustees of Tufts College
  New England Medical Center Hospitals, Inc.
  1149336 Ontario, Inc.
  One aspect of the present invention relates to a method for treating Type II diabetes in an animal, comprising conjointly administering to the animal metformin and an inhibitor of dipeptidylpeptidase IV or a pharmaceutically acceptable salt thereof in an amount sufficient to treat Type II diabetes of the animal.
  
  Patent expiration dates:
  
  
  • February 2, 2019
    
    ✓ 
    Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH METFORMIN
  
  

See also...

• Juvisync Consumer Information (Drugs.com)
• Juvisync Consumer Information (Wolters Kluwer)
• Juvisync Consumer Information (Cerner Multum)
• Sitagliptin/Simvastatin Consumer Information (Wolters Kluwer)
• Simvastatin and sitagliptin Consumer Information (Cerner Multum)

Tandospirone

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

N05B

CAS registry number (Chemical Abstracts Service)

0087760-53-0

Chemical Formula

C21-H29-N5-O2

Molecular Weight

383

Therapeutic Categories

Anxiolytic agent

Antidepressant

Chemical Name

(1R,2S,3R,4S)-N-{4-[4-(Pyrimidin-2-yl)-piperazin-1-yl]butyl}-8,9,10-trinobornane-2,3-dicarboximide (1:1)

Foreign Names

• Tandospironum (Latin)
• Tandospiron (German)
• Tandospirone (French)
• Tandospirona (Spanish)

Generic Names

• Tandospirone (OS: BAN)
• SM 3997 (IS: Sumitomo)
• Tandospirone Citrate (OS: USAN, BANM)

Brand Names

• Sediel
  Dainippon, China; Dainippon Sumitomo, Japan

International Drug Name Search

Glossary

BAN	British Approved Name
BANM	British Approved Name (Modified)
IS	Inofficial Synonym
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Nicotine Transdermal System

Ingredient matches for Nicotine Transdermal System

Nicotine

Nicotine is reported as an ingredient of Nicotine Transdermal System in the following countries:

• United States

International Drug Name Search

Ceglution

Ceglution may be available in the countries listed below.

Ingredient matches for Ceglution

Lithium

Lithium carbonate (a derivative of Lithium) is reported as an ingredient of Ceglution in the following countries:

• Argentina


• Ecuador

International Drug Name Search